Navigation Links
Watson Launches Generic LoSEASONIQUE(R)
Date:12/7/2011

PARSIPPANY, N.J., Dec. 7, 2011 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that under a settlement with Teva Women's Health, Watson has launched Amethia® Lo (levonorgestrel/ethinyl estradiol (0.1mg/0.02mg) and ethinyl estradiol (0.01mg)) tablets, the generic equivalent of Teva Women's Health, Inc.'s  LoSEASONIQUE®. Amethia® Lo tablets are indicated for the prevention of pregnancy.  Terms of the settlement were not disclosed.

As a "first applicant" to submit a substantially complete ANDA, Watson is eligible for 180 days of shared generic market exclusivity.  For the most recent twelve months ending September 30, 2011, LoSEASONIQUE® had sales of approximately $28 million, according to IMS Health data.

About Watson Pharmaceuticals, Inc.Watson Pharmaceuticals, Inc. is an integrated global specialty pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on Urology and Women's Health. Watson has operations in many of the world's established and growing international markets.

For press release and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.

Forward-Looking Statement Statements contained in this press release that refer to non-historical facts are forward-looking statements that reflect Watson's current perspective of existing information as of the date of this release. It is important to note that Watson's goals and expectations are not predictions of actual performance. Actual results may differ materially from Watson's current expectations depending upon a number of factors, risks and uncertainties affecting Watson's business. These factors include, among others, the impact of competitive products and pricing; the timing and success of product launches; difficulties or delays in manufacturing; the availability and pricing of third party sourced products and materials; successful compliance with FDA and other governmental regulations applicable to Watson and its third party manufacturers' facilities, products and/or businesses; changes in the laws and regulations, including Medicare and Medicaid, affecting among other things, pricing and reimbursement of pharmaceutical products; and such other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's quarterly report on form 10-Q for the quarter ended September 30, 2011 and Watson's annual report on Form 10-K for the year ended December 31, 2010. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements.

LoSEASONIQUE® is a registered trademark of Teva Women's Health, Inc.

(Logo:  http://photos.prnewswire.com/prnh/20100121/LA41294LOGO)CONTACTS: Investors: 

Patty Eisenhaur 

(862) 261-8141

 Media: 

Charlie Mayr 

(862) 261-8030   


'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Watson Launches Generic LIPITOR®
2. Watson to Present at the 2011 Piper Jaffray Health Care Conference
3. Watson Wins Kentucky Drug Pricing Litigation
4. Watson Confirms Exelon(R) Patent Challenge
5. Columbia Laboratories and Watson Pharmaceuticals Confirm FDA Advisory Committee to Review Preterm Birth NDA
6. Watson Third Quarter 2011 Net Revenue Climbs 23% to $1.1 Billion; Non-GAAP Diluted EPS of $1.09; GAAP Diluted EPS of $0.54
7. Watson Confirms Court Grants Preliminary Injunction Preventing Launch of Generic LOVENOX®
8. Watson to Present at the 2011 Annual Credit Suisse Health Care Conference
9. Watson Confirms Daytrana(R) Patent Challenge
10. Watson Provides Update on District Court Order Concerning Generic Version of LOVENOX®
11. Watson Confirms District Court Order Concerning Generic Version of LOVENOX(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... Research and Markets has announced the addition of the "Menopause Drugs ... ... Price Analysis and Strategies - 2016, provides drug pricing data and benchmarks ... What are the key drugs marketed for ... Menopause market? What are the unit prices and annual ...
(Date:2/23/2017)... Research and Markets has announced the addition ... 2016" report to their offering. ... The latest research Oesophageal Cancer Drugs Price ... in the global Oesophageal Cancer market. The research answers ... key drugs marketed for Oesophageal Cancer and their clinical attributes? How ...
(Date:2/23/2017)... Calif. , Feb. 23, 2017 ... company focused on the development and commercialization of ... pain, announced that it will release fourth quarter ... Thursday, March 2nd, 2017. AcelRx management will host ... Time (1:30 p.m. Pacific Time) on March 2 ...
Breaking Medicine Technology:
(Date:2/24/2017)... ... 24, 2017 , ... Dr. Ronald E. Hawkins, vice president ... of Peter A. Bell, DO, MBA, HPF, FACOEP-dist., FACEP, as the new dean ... Dr. Bell comes to Liberty from the Ohio University Heritage College of Osteopathic ...
(Date:2/24/2017)... ... February 24, 2017 , ... In the Health Care IT campaign, Robert Herjavec ... it’s not if you will be attacked, but when.” However, he and many others ... health care. , Improvements in auditing and monitoring have taken security in health care ...
(Date:2/24/2017)... Texas (PRWEB) , ... February 24, 2017 , ... ... to The Medical Center at Craig Ranch building at 8080 State Highway 121, Suite ... Medical District with easy access to Highway 121. , As the practice has grown, ...
(Date:2/24/2017)... ... , ... With ProGlass Prism users now have the ability to simulate prism ... position, rotation, distortion, edge softness, edge blur, chromatic aberration, individual glass position offset, anchor ... Prism users are given the tools and effects to generate a fractal prismatic ...
(Date:2/24/2017)... ... February 24, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at ... concerning this present generation. Yisrayl makes an astounding statement when he says that ... explains that the Bible details the current times so plainly that anyone should be ...
Breaking Medicine News(10 mins):